Corrections

Management of obesity: summary of SIGN guideline

BMJ 2010; 340 doi: https://doi.org/10.1136/bmj.c1295 (Published 05 March 2010) Cite this as: BMJ 2010;340:c1295

Owing to a processing error, the print and pdf versions of this Practice article by Jennifer Logue and colleagues (BMJ 2010;340:c154, doi:10.1136/bmj.c154) were not updated to take account of the withdrawal in Europe in January 2010 of sibutramine, formerly a drug used to treat obesity. In two places, therefore, these versions should say: “Consider orlistat” [not “Consider orlistat or sibutramine”]. Orlistat is now the only drug recommended in the treatment of obesity.

Notes

Cite this as: BMJ 2010;340:c1295

View Abstract